Latest filings (excl ownership)
424B3
Prospectus supplement
26 Mar 24
424B3
Prospectus supplement
26 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
10-K/A
2022 FY
Annual report (amended)
25 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
25 Mar 24
424B3
Prospectus supplement
5 Feb 24
424B3
Prospectus supplement
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
22 Dec 23
424B3
Prospectus supplement
15 Dec 23
8-K
Regulation FD Disclosure
5 Dec 23
424B3
Prospectus supplement
30 Nov 23
EFFECT
Notice of effectiveness
30 Nov 23
CORRESP
Correspondence with SEC
28 Nov 23
UPLOAD
Letter from SEC
22 Nov 23
DEF 14A
Definitive proxy
17 Nov 23
S-1
IPO registration
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
PRE 14A
Preliminary proxy
7 Nov 23
D
$2.00 mm in equity, sold $2.00 mm, 1 investor
3 Nov 23
8-K
Coeptis Therapeutics Announces $2 Million Private Placement
27 Oct 23
8-K
Unregistered Sales of Equity Securities
12 Oct 23
424B3
Prospectus supplement
26 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Aug 23
8-K
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
22 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million
16 Jun 23
424B4
Prospectus supplement with pricing info
15 Jun 23
S-1MEF
Registration of additional securities for an S-1
14 Jun 23
EFFECT
Notice of effectiveness
14 Jun 23
S-1MEF
Registration of additional securities for an S-1
13 Jun 23
S-1/A
IPO registration (amended)
12 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
8-K
Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market
9 Jun 23
S-1/A
IPO registration (amended)
6 Jun 23
8-K
Regulation FD Disclosure
5 Jun 23
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Brian Cogley
17 Jan 24
3
Brian Cogley
17 Jan 24
4
Tara DeSilva
16 Jan 24
4
Daniel Alexander Yerace
9 Jan 24
4
Gene Salkind
9 Jan 24
4
David Mehalick
9 Jan 24
4
Christopher P. Cochran
9 Jan 24
4
David Mehalick
11 Dec 23
4
Chris Calise
31 Aug 23
4
Gene Salkind
30 Aug 23
SC 13G/A
Harraden Circle Investments, LLC
15 Feb 23
SC 13G/A
Hudson Bay Capital Management LP
6 Feb 23
4
Daniel Alexander Yerace
31 Jan 23
4
Christine Elise Sheehy
31 Jan 23
4
Gene Salkind
31 Jan 23
4
David Mehalick
31 Jan 23
4
Tara DeSilva
31 Jan 23
4
Philippe Deschamps
31 Jan 23
4
Christopher P. Cochran
31 Jan 23
4
Chris Calise
31 Jan 23
SC 13D
Bull Horn Holdings Sponsor LLC
7 Nov 22
SC 13G/A
Lisa Pharma, LLC
7 Nov 22
SC 13G/A
Lena Pharma, LLC
7 Nov 22
3
Daniel Alexander Yerace
7 Nov 22
3
Christine Elise Sheehy
7 Nov 22
3
Gene Salkind
7 Nov 22
3
David Mehalick
7 Nov 22
3
Tara DeSilva
7 Nov 22
3
Philippe Deschamps
7 Nov 22
3
Christopher P. Cochran
7 Nov 22
4
Robert Striar
1 Nov 22
SC 13G/A
Karpus Management, Inc.
10 May 22
4
Frederick Vincent Jr. Fortmiller
6 May 22
3
Frederick Vincent Jr. Fortmiller
6 May 22
SC 13G
Harraden Circle Investments, LLC
18 Apr 22
SC 13G/A
GLAZER CAPITAL, LLC
14 Feb 22
SC 13G
Karpus Management, Inc.
14 Feb 22
SC 13G/A
Lighthouse Investment Partners, LLC
14 Feb 22
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 22